In This Article:
-
Net Revenue for IGALMI: $214,000 for Q3 2024, compared to $341,000 for Q3 2023.
-
Net Revenue for Nine Months Ended September 30, 2024: $1.9 million, an 89% increase from $1 million in the same period in 2023.
-
Cost of Goods Sold: $1.2 million for Q3 2024, compared to $512,000 for Q3 2023.
-
Research and Development Expenses: $5.1 million for Q3 2024, compared to $19.6 million for Q3 2023.
-
Selling, General, and Administrative Expenses: $7.7 million for Q3 2024, compared to $24.3 million for Q3 2023.
-
Net Loss: $13.7 million for Q3 2024, compared to $50.5 million for Q3 2023.
-
Operating Cash Used: $16.3 million during Q3 2024.
-
Cash and Cash Equivalents: $40.4 million as of September 30, 2024.
Release Date: November 14, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
BioXcel Therapeutics Inc (NASDAQ:BTAI) announced important milestones with two pivotal Phase 3 trials for BXCL501, targeting agitation associated with bipolar disorder, schizophrenia, and Alzheimer's dementia.
-
The SERENITY at home trial for BXCL501 represents a near-term growth opportunity and is the company's immediate focus area.
-
The company received a Department of Defense grant to fund a Phase 2a study of BXCL501 for acute stress disorder, highlighting external validation of its therapeutic potential.
-
Research and development expenses significantly decreased from $19.6 million in Q3 2023 to $5.1 million in Q3 2024, reflecting cost management and reprioritization efforts.
-
BioXcel Therapeutics Inc (NASDAQ:BTAI) reported an 89% increase in net revenue for the nine months ended September 30, 2024, compared to the same period in 2023, indicating rising utilization of IGALMI.
Negative Points
-
Net revenue for IGALMI decreased to $214,000 in Q3 2024 from $341,000 in Q3 2023, primarily due to the timing of reorders from existing customers.
-
The company reported a net loss of $13.7 million for Q3 2024, although this was an improvement from a $50.5 million loss in Q3 2023.
-
Cost of goods sold increased significantly to $1.2 million in Q3 2024 from $512,000 in Q3 2023, due to higher non-cash charges for reserves for excess or obsolete inventory.
-
BioXcel Therapeutics Inc (NASDAQ:BTAI) is working to strengthen its balance sheet and is evaluating strategic financing alternatives, indicating potential financial challenges.
-
The TRANQUILITY In-Care trial protocol had to be adjusted following FDA feedback, which could impact timelines and resource allocation.
Q & A Highlights
Q: How has the launch of the SERENITY study gone so far, and what is the expected rate of enrollment? A: Vincent O'Neill, Chief of Product Development and Medical Officer, explained that the study has kicked off with the first patient randomized recently. They are in the ramp-up phase, which is typical for such studies. Despite the holiday season potentially slowing down site activity, they expect a rebound in January. With 26 active sites for 200 patients, they are comfortable with the nine to 12-month timeline.